Compare · ARGX vs PROK
ARGX vs PROK
Side-by-side comparison of argenx SE (ARGX) and ProKidney Corp. (PROK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and PROK operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.41B, about 109.1x PROK ($489.3M).
- Over the past year, ARGX is up 52.5% and PROK is down 48.2% - ARGX leads by 100.7 points.
- ARGX has been more active in the news (3 items in the past 4 weeks vs 1 for PROK).
- ARGX has more recent analyst coverage (25 ratings vs 13 for PROK).
- Company
- argenx SE
- ProKidney Corp.
- Price
- $861.30+0.30%
- $1.63+0.62%
- Market cap
- $53.41B
- $489.3M
- 1M return
- -1.91%
- -4.68%
- 1Y return
- +52.49%
- -48.17%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 3
- 1
- Recent ratings
- 25
- 13
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Latest PROK
- SEC Form 4 filed by Chief Technical Officer Locke Kenneth Thomas
- Chief Legal Officer Girolamo Todd C converted options into 163,857 shares, increasing direct ownership by 100% to 327,713 units (SEC Form 4)
- SEC Form 3 filed by new insider Locke Kenneth Thomas
- ProKidney Appoints Kenneth Locke as Chief Technical Officer
- SEC Form 4 filed by Director Jimenez Santos Jose Ignacio
- SEC Form 4 filed by Director Lotvin Alan
- SEC Form 4 filed by Director Fox Jennifer A.
- SEC Form 4 filed by Director Doyle William F
- SEC Form 4 filed by Director Sinha Uma
- SEC Form 4 filed by Director Legorreta Pablo G.